Clinical trials: Hepatitis C Virus
Hepatitis C
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
This study will assess the efficacy, safety, and tolerability of 16 or 24 weeks of sofosbuvir (Sovaldi®; SOF) + ribavirin (RBV), and 12 weeks of SOF+RBV+ pegylated interferon (Peg-IFN) in treatment-naive and treatment-experienced…
- Trial name
- NCT01962441
- Testing
- SOF, RBV, Peg-IFN
- Where
- 78 sites in United States, Australia and 3 more
- Volunteers
- 601 people
- Sponsor
- Gilead Sciences
Hepatitis C
A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)
This study will compare two different durations of treatment with grazoprevir (MK-5172) in combination with ribavirin (RBV) in treatment-naïve non-cirrhotic interferon-eligible interleukin 28b CC (IL28B CC) genotype participants…
- Trial name
- NCT01716156
- Testing
- Grazoprevir, Ribavirin
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Viral Infection, Chronic Hepatitis C
A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve participants with genotype 4 hepatitis C…
- Conditions
- Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
- Trial name
- NCT02593162
- Testing
- Faldaprevir, TD-6450, Ribavirin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Trek Therapeutics, PBC
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/ritonavir/ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02725866
- Testing
- Paritaprevir/ritonavir/ombitasvir, Dasabuvir, Ribavirin
- Volunteers
- 216 people
- Sponsor
- AbbVie
Hepatitis C Virus
Drug Interaction Oral Contraceptive Pill (OCP)
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
- Trial name
- NCT01063023
- Testing
- Ortho Tri-Cyclen®, BMS-650032
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.
- Trial name
- STEALTHC-3 (NCT00637923)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 112 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis C Virus Infection
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
The purpose of this study is to evaluate if the DNA vaccine CHRONVAC-C® intended for future treatment of Hepatitis C infections is safe and tolerated when administered to HCV infected individuals with a low viral load.
- Trial name
- NCT00563173
- Testing
- CHRONVAC-C®
- Where
- 2 sites in Sweden
- Volunteers
- 12 people
- Sponsor
- Tripep AB
Hepatitis C, Chronic, Hepatitis C
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
The objective of the study is to assess the safety and efficacy of Intron A (3 Mio I.E./m2, 3 times per week) and Rebetol (15 mg/kg/day) in children aged 3 to 17, treated in common medical practice at 10 sites in Germany.
- Trial name
- NCT00727077
- Testing
- IntronA (interferon alfa-2b; SCH 30500), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Virological Response Study of the HCV Vaccine IC41
The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41. Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.
- Trial name
- NCT00601770
- Testing
- IC41
- Where
- 8 sites in Germany, Poland and 1 more
- Volunteers
- 71 people
- Sponsor
- Valneva Austria GmbH
Hepatitis C, Chronic
A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients
The purpose of this study is to evaluate the efficacy and safety of TMC435 compared with placebo in combination with peginterferon alfa-2a (pegIFN alfa-2a) and ribavirin in treatment-naive patients with chronic genotype 1…
- Trial name
- NCT01292239
- Testing
- TMC435, Peginterferon alfa-2a (pegIFN alfa-2a), Ribavirin (RBV)
- Where
- 28 sites in Japan
- Volunteers
- 183 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C, Chronic
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (PegIntron®/peg-IFN) and ribavirin (RBV) in chronic hepatitis C (CHC) Genotype I…
- Trial name
- NCT01405937
- Testing
- vaniprevir, peg-IFN, ribavirin
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Chronic
Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C
The purpose of this study is to collect information on the efficacy, safety and tolerability of telaprevir (in combination with other medications), in patients who have a history of intravenous drug use with genotype 1 chronic…
- Trial name
- INTEGRATE (NCT01980290)
- Where
- 18 sites in Belgium, France and 4 more
- Volunteers
- 50 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Liver Fibrosis, Cirrhosis
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with…
- Trial name
- NCT00043303
- Testing
- interferon gamma-1b
- Volunteers
- 502 people
- Sponsor
- InterMune
Hepatitis C
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
- Trial name
- NCT01258686
- Testing
- Silymarin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis C, Hepatitis C, Chronic
Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
The goal of this study is to elucidate the reasons why patients with chronic hepatitis C (CHC) would not be considered eligible for antiviral treatment.
- Trial name
- NCT00724451
- Testing
- Peginterferon alfa-2b, Ribavirin, Peginterferon alfa-2a
- Volunteers
- 1,128 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C.
- Trial name
- NCT00372983
- Testing
- NOV-205
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Liver Transplant
Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems.
- Trial name
- NCT00238901
- Testing
- Basiliximab
- Volunteers
- 194 people
- Sponsor
- Novartis
HCV Infection
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
- Trial name
- NCT00931281
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Abbott